The 2021 PDBP Annual Consortium Meeting was held virtually on August 16-17, 2021. Principal Investigators (PIs), clinical coordinators and data management experts from each PDBP project, PDBP participants and caregivers, as well as representatives from the National Institutes of Health (NIH), PD nonprofit organizations, and the pharmaceutical industry met to discuss progress over the last twelve months in addition to current and future plans for the program.
The PDBP Annual Consortium Meeting was held as a virtual meeting on August 17-18, 2020. The meeting provided a forum for participating scientists and stakeholders to discuss recent progress and emergent opportunities in Parkinson's disease (PD), Lewy body dementia (LBD) and related Parkinsonisms biomarker research.
The PDBP Annual Consortium Meeting was held August 12-13, 2019 in Rockville, MD. Principal investigators (PIs), clinical and data management experts from each PDBP project, and representatives from the NIH, PD nonprofit organizations , and the pharmaceutical industry met to discuss progress over the last twelve months in addition to current and future plans for the program.
Accelerating Medicines Partnership launches data knowledge portal for Parkinson’s disease
Shared platform to catalyze research collaboration toward biomarker discovery to advance the development disease therapies
The Accelerating Medicines Partnership (AMP) program for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy controls to researchers working to develop effective therapies for the disease. The portal enables researchers to study complex data sets and perform genome-wide analyses at a scale previously impossible.
Accelerating Research for Parkinson’s Disease
The Accelerating Medicines Partnership Parkinson's disease (AMP PD) program, launched on Jan 30, 2018, is the most ambitious initiative so far to find a cure for Parkinson's disease. Formed by the US National Institutes of Health (NIH), the US Food and Drug Administration (FDA), five biopharmaceutical and life science companies, and the Michael J. Fox Foundation, this partnership is focused on discovering novel therapeutic targets and on developing biomarkers to help validate existing therapeutic targets for Parkinson's disease.
NIH launches partnership to improve success of clinical trials for patients with Parkinson’s disease
“Advancing treatments for Parkinson’s disease is hampered by insufficient understanding of biological networks; drugs aimed at seemingly promising therapeutic targets fail in clinical trials,” said NIH Director Francis S. Collins, M.D., Ph.D. “By combining our expertise and resources, AMP PD partners hope to increase our collective odds of success in accelerating the development of effective treatments for a million Americans who suffer from this debilitating disease.”